Preliminary Efficacy of Different Exercise Training During Immunotherapy in Patients With Lung Cancer: The ENHANCE Trial

ConditionLung Cancer
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorDana-Farber Cancer Institute

About this trial

The purpose of this study is to examine the feasibility and effects of 12-week exercise training at different intensities among individuals with advanced lung cancer receiving immune checkpoint inhibitors.

The names of the study interventions involved in this study are:

* High-intensity interval training (HIIT) * Moderate-intensity continuous training (MICT) * Usual care (UC)

Eligibility criteria

Qualifiers

Age ≥18 years.

Histologically diagnosed with non-small cell lung cancer (NSCLC).

Having been receiving immunotherapy for at least one month with a plan to continue for at least 12 weeks prospectively at the time of recruitment.

Medical clearance to perform exercise intervention and testing by their treating oncologist.

Disqualifiers

Participate in more than 60 minutes of moderate-to-vigorous aerobic exercise per week over the past month. This study targets insufficiently active persons to assess the effect of the described exercise intervention, where additional exercise done regularly will contaminate the intervention outcomes.

Unstable comorbidities that prevent participation in moderate-to-vigorous intensity exercise. Patients with unstable comorbidities may develop unexpected adverse events from exercise. For the purpose of patients' safety, as well as because part of this study involves remote, home-based exercise where close supervision is not possible, patients with unstable medical conditions are excluded.

Subjects who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study.

Development of second malignancy (except for basal cell carcinoma or squamous cell carcinoma of the skin) that requires concurrent treatment, which would interfere with this study.

Trial design

Treatments tested in this trial

  • High-Intensity Interval Training (HIIT)
  • Moderate-Intensity Continuous Training (MICT)

Treatment groups

30 Participants
are divided into 3 treatment groups

Sponsors and collaborators

Dana-Farber Cancer Institute

Lead sponsor

National Cancer Institute (NCI)

Collaborator